Passage Bio (NYSE:GFL) had its price target upped by TD Securities from $27.00 to $29.00 in a report released on Friday morning, The Fly reports. The brokerage currently has a hold rating on the stock.
GFL has been the subject of a number of other research reports. BMO Capital Markets initiated coverage on shares of Passage Bio in a research report on Tuesday, March 31st. They set an outperform rating and a $19.00 target price for the company. Barclays initiated coverage on shares of Passage Bio in a research report on Monday, March 30th. They set an equal weight rating and a $20.00 target price for the company. CIBC increased their target price on shares of Passage Bio from $27.00 to $28.00 and gave the stock a neutral rating in a research report on Wednesday, May 13th. Zacks Investment Research cut Passage Bio from a buy rating to a hold rating in a report on Monday, June 15th. Finally, Goldman Sachs Group assumed coverage on Passage Bio in a report on Monday, March 30th. They issued a neutral rating for the company. Six equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Passage Bio currently has an average rating of Buy and an average target price of $23.05.
GFL opened at $18.75 on Friday. The business’s 50 day simple moving average is $18.37. Passage Bio has a 1 year low of $11.92 and a 1 year high of $20.97.
About Passage Bio
GFL Environmental Inc operates as a diversified environmental services company in North America. The company offers non-hazardous solid waste management, infrastructure and soil remediation, and liquid waste management services. Its solid waste management business line includes the collection, transportation, transfer, recycling, and disposal of non-hazardous solid waste for municipal, residential, and commercial and industrial customers.
Featured Article: What is the role of the G-20?
Receive News & Ratings for Passage Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Passage Bio and related companies with MarketBeat.com's FREE daily email newsletter.